Daniel J. Wackelin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel J. Wackelin has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anuvab Das
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States
1 shared publication - Cooper S. Jamieson
Department of Chemistry and Biochemistry, University of California, Los Angeles, USA
1 shared publication - Doris Mia Taylor
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States
1 shared publication - Edmond Y. Lau
Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, 7000 East Avenue, Livermore, CA 94550, USA
1 shared publication Erick G. Ortiz
Lawrence Livermore National Laboratory, Materials Science Division, 7000 East Avenue, Livermore, CA 94550, USA
1 shared publication- Frances H. Arnold
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States
1 shared publication
Latest Publications
- 23 February 2026
- Published by Elsevier in Journal of Biotechnology
- Vol. 413, 42-50
Engineering an aldoxime dehydratase with high activity and isomer tolerance for biosynthesis of an O-protected primary cyanohydrin
- 23 February 2026
- Published by Elsevier in Journal of Biotechnology
- Vol. 413, 42-50
Engineering an aldoxime dehydratase with high activity and isomer tolerance for biosynthesis of an O-protected primary cyanohydrin
- 11 July 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (29) , 16176-16185
Enantio- and Diastereoenriched Enzymatic Synthesis of 1,2,3-Polysubstituted Cyclopropanes from (Z/E)-Trisubstituted Enol Acetates
In nature and synthetic chemistry, stereoselective [2 + 1] cyclopropanation is the most prevalent strategy for the synthesis of chiral cyclopropanes, a class of key pharmacophores in pharmaceuticals and bioactive natural products. One of the most extensively studied reactions in the organic chemist's arsenal, stereoselective [2 + 1] cyclopropanation, largely relies on the use of stereodefined olefins, which can require elaborate laboratory synthesis or tedious separation to ensure high stereoselectivity. Here, we report engineered hemoproteins derived from a bacterial cytochrome P450 that catalyze the synthesis of chiral 1,2,3-polysubstituted cyclopropanes, regardless of the stereopurity of the olefin substrates used. Cytochrome P450BM3 variant P411-INC-5185 exclusively converts (Z)-enol acetates to enantio- and diastereoenriched cyclopropanes and in the model reaction delivers a leftover (E)-enol acetate with 98% stereopurity, using whole Escherichia coli cells. P411-INC-5185 was further engineered with a single mutation to enable the biotransformation of (E)-enol acetates to α-branched ketones with high levels of enantioselectivity while simultaneously catalyzing the cyclopropanation of (Z)-enol acetates with excellent activities and selectivities. We conducted docking studies and molecular dynamics simulations to understand how active-site residues distinguish between the substrate isomers and enable the enzyme to perform these distinct transformations with such high selectivities. Computational studies suggest the observed enantio- and diastereoselectivities are achieved through a stepwise pathway. These biotransformations streamline the synthesis of chiral 1,2,3-polysubstituted cyclopropanes from readily available mixtures of (Z/E)-olefins, adding a new dimension to classical cyclopropanation methods.
- 11 July 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (29) , 16176-16185
Enantio- and Diastereoenriched Enzymatic Synthesis of 1,2,3-Polysubstituted Cyclopropanes from (Z/E)-Trisubstituted Enol Acetates
In nature and synthetic chemistry, stereoselective [2 + 1] cyclopropanation is the most prevalent strategy for the synthesis of chiral cyclopropanes, a class of key pharmacophores in pharmaceuticals and bioactive natural products. One of the most extensively studied reactions in the organic chemist's arsenal, stereoselective [2 + 1] cyclopropanation, largely relies on the use of stereodefined olefins, which can require elaborate laboratory synthesis or tedious separation to ensure high stereoselectivity. Here, we report engineered hemoproteins derived from a bacterial cytochrome P450 that catalyze the synthesis of chiral 1,2,3-polysubstituted cyclopropanes, regardless of the stereopurity of the olefin substrates used. Cytochrome P450BM3 variant P411-INC-5185 exclusively converts (Z)-enol acetates to enantio- and diastereoenriched cyclopropanes and in the model reaction delivers a leftover (E)-enol acetate with 98% stereopurity, using whole Escherichia coli cells. P411-INC-5185 was further engineered with a single mutation to enable the biotransformation of (E)-enol acetates to α-branched ketones with high levels of enantioselectivity while simultaneously catalyzing the cyclopropanation of (Z)-enol acetates with excellent activities and selectivities. We conducted docking studies and molecular dynamics simulations to understand how active-site residues distinguish between the substrate isomers and enable the enzyme to perform these distinct transformations with such high selectivities. Computational studies suggest the observed enantio- and diastereoselectivities are achieved through a stepwise pathway. These biotransformations streamline the synthesis of chiral 1,2,3-polysubstituted cyclopropanes from readily available mixtures of (Z/E)-olefins, adding a new dimension to classical cyclopropanation methods.